Vanadis-02 is under clinical development by CFM Pharma and currently in Phase I for Burns. According to GlobalData, Phase I drugs for Burns have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Vanadis-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vanadis-02 is under development for the treatment of second and third-degree burns. It is administered by intravenous route. The therapeutic candidate constitutes bis-maltolato-oxo-vanadium, an organic vanadium salt. It acts by targeting protein tyrosine phosphatases.
CFM Pharma overview
CFM Pharma is a pharmaceutical company that develops drugs for acute traumatic diseases and heart infarctions. The company offers solutions for heart attack, second-and third-degree burns, acute renal failure, and others. It provides service such as renal ischemia (hypotension, sepsis ), toxic causes (drugs or contrast medium), and other traumatic injuries. CFM Pharma provides Vanadis, a drug used to cure tissue damage, heart reperfusion damages, kidney injuries, and others. The company has business presence in Europe, the USA, Japan, and others. CFM Pharma is headquartered in IJsselstein, Utrecht, the Netherlands.
For a complete picture of Vanadis-02’s drug-specific PTSR and LoA scores, buy the report here.